Immuno-Oncology | Specialty

Pembrolizumab Combo Generates High Response Rate in Refractory Myeloma

December 7th 2015

The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.

Dr. Lawrence Fong on Managing the Side Effects of Immunotherapies

December 7th 2015

Lawrence Fong, MD, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, discusses the importance of educating oncologists on the side effects of immunotherapies.

Immunotherapy Shows Early Promise in Advanced Sarcomas

December 7th 2015

Phase Ib/II research has shown promise for adoptive cellular therapy combined with ipilimumab in patients with advanced sarcomas.

CAR T-Cell Infusion Leads to Eradication of Myeloma

December 5th 2015

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.

Dr. Tara Gangadhar on Epacadostat/ Pembrolizumab Combination

December 1st 2015

Tara C. Mitchell, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discuses preliminary results from a phase I/11 study of epacadostat in combination with pembrolizumab.

PD-1 Inhibitors Advance Rapidly for Broad Cohort in NSCLC

December 1st 2015

As the class of agents targeting the PD-1/PD-L1 pathway expands in non–small cell lung cancer, so does the potential population of patients who would be candidates for the groundbreaking immunotherapy.

Suresh Ramalingam on Remaining Questions With Checkpoint Inhibitors in NSCLC

December 1st 2015

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Durvalumab/Tremelimumab Combo Shows Promise in NSCLC, Regardless of PD-L1 Status

December 1st 2015

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.

Dr. Garon on Incorporating Immunotherapies Into Lung Cancer Treatment

November 30th 2015

dward Garon, MD, assistant professor of Medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles, discusses incorporating immunotherapies into the treatment of patients with lung cancer.

James Allison on the Future of Checkpoint Inhibitors in Melanoma

November 30th 2015

James Allison, PhD, discusses the rapidly expanding field of immunotherapy in melanoma.

FDA Issues Complete Response Letter for Nivolumab in BRAF-Mutant Melanoma

November 27th 2015

The FDA has requested additional data for the use of single-agent nivolumab in previously untreated patients with BRAF V600 mutation-positive advanced melanoma.

Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma

November 27th 2015

Dirk Schadendorf, MD, Head of Department for Dermatology, Venerology und Allergology, University Hospital Essen, Germany, discusses the results from the phase III CheckMate 067 study, which looked at a combination immunotherapy regimen in advanced melanoma.

Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in Melanoma

November 25th 2015

Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.

FDA Approves Frontline Nivolumab for Advanced Melanoma

November 24th 2015

The FDA has expanded the approval for single-agent nivolumab (Opdivo) to include the frontline treatment of patients with BRAF wild-type advanced melanoma.

FDA Approves First-Line Nivolumab for Advanced Melanoma

November 24th 2015

FDA Approves Nivolumab for Metastatic Renal Cell Carcinoma

November 23rd 2015

The FDA has approved nivolumab as a treatment for patients with metastatic renal cell carcinoma following prior treatment with an anti-angiogenic therapy.

Pembrolizumab/Ipilimumab Combo Effective in Advanced Melanoma

November 22nd 2015

A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

November 22nd 2015

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM

November 22nd 2015

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

Novel Pembrolizumab Combos Show Promising Responses in Melanoma

November 21st 2015

Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.